Abstract
EGFR-mutated non-small-cell lung cancer (NSCLC) responds well to EGFR tyrosine-kinase inhibitors such as erlotinib. Median progression-free survival (PFS) reported in the erlotinib group of the European Tarceva versus Chemotherapy (EURTAC) trial 1 Rosell R Carcereny E Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13: 239-246 Summary Full Text Full Text PDF PubMed Scopus (4347) Google Scholar was 9·7 months compared with 5·2 months in the standard chemotherapy group (hazard ratio [HR] 0·37, 95% CI 0·25–0·54; p<0·0001). The HR for progression in EURTAC was much the same as the pooled HR for progression of 0·23 (95% CI 0·19–0·27) reported in four randomised studies in Asian patients. 1 Rosell R Carcereny E Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13: 239-246 Summary Full Text Full Text PDF PubMed Scopus (4347) Google Scholar However, the disease-free time to progression was still less than 1 year in EURTAC, 1 Rosell R Carcereny E Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13: 239-246 Summary Full Text Full Text PDF PubMed Scopus (4347) Google Scholar and thus identification of mechanisms of acquired resistance, including to the EGFR T790M resistance mutation, is crucial. To this end, a second biopsy at the time of progression is becoming increasingly accepted. However, often only a small amount of tumour is obtained and, to circumvent the problem of access to tissue samples, studies have focused on circulating tumour DNA (ctDNA) in plasma or serum. ctDNA can be used as a liquid biopsy, allowing repeated blood samples to be taken and changes in mutation status to be tracked throughout a cancer treatment, paving the way for a potential use in following up of treatment response, gauging prognosis, or monitoring of recurrence. 2 Schwarzenbach H Hoon DS Pantel K Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011; 11: 426-437 Crossref PubMed Scopus (1971) Google Scholar
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.